Quoin Pharmaceuticals, Ltd.

Quoin reported cash and marketable securities of approximately $10.7 million as of December 31, compared with $14 million as of September 30. Net loss for full-year 2023 was $8.7 million versus $9.4 million in 2022, and fourth-quarter net loss was $2 million in both Q4 2023 and Q4 2022. The company said the $6.5 million public offering completed last week should fund operations into the second half of 2025, and that an $8 million ELOC, when accessed, could extend cash into the second half of 2026. Management did not provide revenue, EPS, or gross margin figures, and did not issue traditional product revenue guidance.

CEO Michael Myers framed 2023 as a “truly transformational year,” emphasizing the first-ever clinical data in Netherton syndrome under an open IND and describing the initial efficacy and safety findings as encouraging. He said the protocol changes were made from a position of strength to build a broader dataset and improve the odds of approval and a broad label. He also stressed that adding pediatric patients should improve recruitment, that the company is building a global commercialization network, and that Quoin remains focused on rare/orphan diseases for potential M&A.

CFO Gordon Dunn said cash and marketable securities were approximately $10.7 million at year-end, down from $14 million at September 30, and highlighted the subsequent $6.5 million offering plus an $8 million ELOC as key liquidity supports. He reported full-year net loss of $8.7 million versus $9.4 million in 2022, attributing the improvement mainly to higher interest income and lower professional and other G&A costs, partly offset by higher R&D spending. He also noted Q4 net loss of $2 million, unchanged from the prior-year quarter.

Analysts focused on pediatric enrollment, timing of data, tolerability of twice-daily dosing, and M&A. Management said it will enroll as many pediatric patients as possible, expects the study mix to skew younger, and has not yet discussed a hard safety-database number with the FDA. On timing, the company expects an open-label readout this summer and initial blinded-study data in early 2025; management also said an FDA discussion on rare pediatric/orphan priority should happen sometime this year. On M&A, Quoin said it has reviewed many distressed assets, prefers later-stage rare/orphan assets with clinical data, and may seek outside capital for any deal rather than use operating cash.